Key Highlights

  • 80% of patients achieved immunosuppression-free clinical response by day 15
  • 33% of patients reached full clinical remission
  • Study led by Memorial Sloan Kettering in immune-mediated enterocolitis
  • No therapy-related severe adverse events reported
  • Biomarker data showed reduced gut inflammation and improved mucosal integrity

Seres Therapeutics, Inc. reported encouraging primary data from a Phase 1b investigator-led study of SER-155, its live biotherapeutic candidate for immune-mediated enterocolitis, a condition in which the gut's immune response becomes dysregulated, often as a complication of cancer immunotherapy. The trial, conducted by researchers at Memorial Sloan Kettering, showed that 80% of participants achieved an immunosuppression-free clinical response by day 15, meeting the study's primary goal: symptom relief without resorting to systemic steroids, which can compromise the very oncology treatments that triggered the immune complication in the first place.

The depth of response drew particular attention from the oncology community. A third of patients — 33% — achieved full clinical remission, a result supported by biomarker evidence showing measurable decreases in gut inflammation and improvements in mucosal integrity. Because immune-mediated enterocolitis frequently forces oncologists to pause or discontinue checkpoint inhibitor therapy while managing the complication, a treatment that resolves gut inflammation without systemic steroids could, in principle, allow patients to remain on their cancer treatment for longer.

Safety data reinforced the encouraging efficacy signal. The study reported no therapy-related severe adverse events, an important marker for a live biotherapeutic product being tested in an already immunocompromised or treatment-fragile patient population. Live biotherapeutics — products composed of living microorganisms designed to restore healthy microbiome function — carry theoretical safety considerations distinct from small-molecule or biologic drugs, making a clean safety profile a meaningful de-risking event for the broader platform.

With the data in hand, Seres is now pursuing strategic collaborations with oncology-focused pharmaceutical companies to advance SER-155 further, a path that reflects both the asset's direct relevance to checkpoint inhibitor-treated cancer patients and the company's own capital position following a previously disclosed funding pause on the program.

What was the primary result of the SER-155 Phase 1b study?

80% of participants achieved an immunosuppression-free clinical response by day 15, with 33% reaching full clinical remission and no therapy-related severe adverse events reported.

Why does SER-155 matter for cancer patients specifically?

Immune-mediated enterocolitis often forces pauses in checkpoint inhibitor treatment; a therapy that resolves it without systemic steroids could allow patients to continue their cancer treatment for longer.

This article is for informational purposes and does not constitute investment advice.